Articles
Rare disease drug Vimizim gets NICE 'yes' – but needs real-w...
NICE says it can approve BioMarin's ultra-rare drug treatment Vimizim, but has proposed real-world data collection and a price cap to overcome doubts about the drug's value, reports Andrew McCo